HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Glucagonoma

An almost always malignant GLUCAGON-secreting tumor derived from the PANCREATIC ALPHA CELLS. It is characterized by a distinctive migratory ERYTHEMA; WEIGHT LOSS; STOMATITIS; GLOSSITIS; DIABETES MELLITUS; hypoaminoacidemia; and normochromic normocytic ANEMIA.
Also Known As:
Adenoma, alpha Cell; Adenomas, alpha-Cell; Glucagonomas; Tumor, alpha-Cell; Tumors, alpha-Cell; alpha Cell Tumor; alpha-Cell Adenoma; alpha-Cell Adenomas; alpha-Cell Tumors; Adenoma, alpha-Cell; alpha-Cell Tumor
Networked: 317 relevant articles (11 outcomes, 14 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1. Neoplasm Metastasis (Metastasis)
2. Neoplasms (Cancer)
3. Gastrinoma
4. Carcinoid Tumor (Carcinoid)
5. Insulinoma

Experts

1. Komoto, Izumi: 3 articles (10/2013 - 11/2002)
2. Imamura, Masayuki: 3 articles (10/2013 - 11/2002)
3. Fujikura, Junji: 3 articles (01/2013 - 11/2002)
4. Hosoda, Kiminori: 3 articles (01/2013 - 11/2002)
5. Doi, Ryuichiro: 3 articles (01/2013 - 11/2002)
6. Nakao, Kazuwa: 3 articles (01/2013 - 11/2002)
7. Tomita, Tsutomu: 3 articles (01/2013 - 11/2002)
8. Tomita, T: 3 articles (05/2006 - 04/2000)
9. Anlauf, M: 2 articles (06/2014 - 06/2011)
10. Linder, Keith E: 2 articles (08/2013 - 10/2010)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Glucagonoma:
1. Octreotide (Sandostatin)FDA LinkGeneric
2. Dacarbazine (DIC)FDA LinkGeneric
3. Glucagon (Glukagon)FDA Link
4. Somatostatin (Somatotropin Release-Inhibiting Factor)IBA
5. Messenger RNA (mRNA)IBA
6. HormonesIBA
7. GastrinsIBA
8. Fluorouracil (Carac)FDA LinkGeneric
9. WDHA syndromeIBA
10. thymidine 5'-triphosphate (TTP)IBA

Therapies and Procedures

1. Drug Therapy (Chemotherapy)
2. Pancreaticoduodenectomy
3. Injections
4. Subcutaneous Injections
5. Pancreatectomy
01/01/2014 - "We report a case of a meso-pancreatectomy performed on a pancreatic glucagonoma in a 58 years-old woman. "
03/01/2005 - "[Median pancreatectomy for early glucagonoma]."
05/01/1983 - "[Malignant pancreatic glucagonoma treated by total radical pancreatectomy. "
01/01/2003 - "Glucagonoma of the pancreas was diagnosed, and distal pancreatectomy with splenectomy was performed. "
09/01/1998 - "This study retrospectively reviews the patients who underwent surgery for these tumors at The Johns Hopkins Hospital from 1949 to 1996, inclusive There were 125 patients (65 males and 60 females) whose mean age was 51 +/- 1 years Fifty-eight patients (48%) had nonfunctional tumors, whereas 64 (52%) had functional tumors 35 (55%) insulinomas, 23 (36%) gastrmomas, three (5%) VIP-omas, two (3 %) glucagonomas, and one (1%) ACTHorna All patients with functional tumors presented with appropriate signs and symptoms of hormonal excess, 86% of patients with nonfunctional tumors presented with weight loss, abdominal pain, or jaundice Preoperaüve computed tomography (CT) correctly localized the tumor in 66 (76%) of 87 patients, angiography in 45 (58%) of 78 patients, and CT plus angiography in 54 (79%) of 68 patients Tumors were benign in 60 patients (48%), malignant m 65 patients (52%), and were located in the head, neck, or uncinate process of the pancreas in 54, body in 14, tail in 18, and duodenum in eight The most common operative procedures performed were 50 pancreaacoduodenectomies (40%), 39 distal pancreatectomies (31%), and 21 tumor enucleations (17%) Nine synchronous hepatic resections were performed for métastases Of the evaluable patients, 46 (43%) had postoperative complications, the most common of which were pancreatic fistula (16%), wound infection (15%), and delayed gastric emptying (8%) There were three in-hospital deaths (2 8%) With a mean follow-up of 55 +/-6 months, there have been 30 additional deaths, 23 of which were related to disease progression The overall 2-, 5-, and 10-year actuarial survival rates were 82%, 65%, and 47%, respectively The 5-year survival for patients with functional tumors was 77% compared to 52% for those with nonfunctional tumors (P = 0 025), the 5-year survival for patients with benign tumors was 91% compared to 49% for those with malignant tumors (P = 0 0004) By univanate analysis the most powerful predictor of poor outcome for patients with malignant tumors (n = 60) was positive surgiad margins (P = 0 006) This single-institution experience documents low mortality and moderate morbidity for patients treated operatively for pancreatic and penpancreaac neuroendocrine tumors The most favorable outcomes are observed in patients with benign functional tumors and in those with completely resected malignant tumors."